Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 10:10 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–17 of 17 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: C3 Glomerulopathy Clear all

Conditions: Glomerulonephritis
Interventions: LNP023; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: C3G
Interventions: Placebo, iptacopan; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years to 60 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 13
States / cities: Aurora, Colorado • Miami, Florida • Lawrenceville, Georgia + 9 more

Conditions: Complement Mediated Diseases
Interventions: AMY-101; Drug
Lead sponsor: Amyndas Pharmaceuticals S.A.; Industry
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: High Point, North Carolina

Conditions: C3 Glomerulopathy, C3 Glomerulonephritis, Dense Deposit Disease
Interventions: Danicopan, Placebo; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 17 Years to 65 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 6
States / cities: Aurora, Colorado • Lawrenceville, Georgia • Iowa City, Iowa + 2 more

Conditions: C3 Glomerulopathy, Immune-complex-membranoproliferative Glomerulonephritis
Interventions: LNP023; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years to 100 Years
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2036
U.S. locations: 5
States / cities: Aurora, Colorado • Lawrenceville, Georgia • Iowa City, Iowa + 2 more

Conditions: IgA Nephropathy (IgAN), IgA Vasculitis, Idiopathic Immune Complex Glomerulonephritis, C3 Glomerulopathy, Membranous Nephropathy, Focal and Segmental Glomerulosclerosis, Minimal Change Disease, Anti-Neutrophilic Cytoplasmic Antibody-GN (ANCA), Lupus Nephritis (LN), Alport Syndrome, Infection-related or Post-infectious Glomerulonephritis, Idiopathic Nephrotic Syndrome (INS)
Interventions: Not listed
Lead sponsor: Pediatric Nephrology Research Consortium; Other
Eligibility: Up to 18 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 2
States / cities: Boston, Massachusetts • Cincinnati, Ohio

Conditions: C3 Glomerulopathy (C3G)
Interventions: Avacopan, Avacopan Matching Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 12 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 10
States / cities: Palo Alto, California • Chicago, Illinois • Iowa City, Iowa + 7 more

Conditions: C3 Glomerulopathy
Interventions: Not listed
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: IgAN, LN, MN, C3G
Interventions: OMS721 (narsoplimab); Biological
Lead sponsor: Omeros Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 8
States / cities: Denver, Colorado • Augusta, Georgia • Lawrenceville, Georgia + 5 more

Conditions: IgA Nephropathy, Lupus Nephritis (LN), C3 (Complement Component 3) Glomerulopathy
Interventions: ADX-097; Drug
Lead sponsor: Akebia Therapeutics; Industry
Eligibility: 16 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Hollywood, Florida • Lawrenceville, Georgia • Orangeburg, South Carolina

Conditions: C3G, IC-MPGN, C3 Glomerulopathy, C3 Glomerulonephritis, Complement 3 Glomerulopathy, Complement 3 Glomerulopathy (C3G), Complement 3 Glomerulonephritis, Dense Deposit Disease, DDD, Membranoproliferative Glomerulonephritis, Membranoproliferative Glomerulonephritis (MPGN), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
Interventions: Pegcetacoplan, Placebo; Drug · Other
Lead sponsor: Apellis Pharmaceuticals, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 26
States / cities: Birmingham, Alabama • Los Angeles, California • Orange, California + 20 more

Conditions: Membranoproliferative Glomerulonephritis
Interventions: Daratumumab; Drug
Lead sponsor: Fernando Fervenza; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: C3 Glomerulonephritis, C3 Glomerulopathy, Immune Complex Membranoproliferative Glomerulonephritis, IC-MPGN, Dense Deposit Disease
Interventions: Danicopan; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 6
States / cities: Birmingham, Alabama • Stanford, California • New Haven, Connecticut + 3 more

Conditions: IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, C3 Glomerulonephritis, Dense Deposit Disease
Interventions: APL-2; Drug
Lead sponsor: Apellis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 17
States / cities: Stanford, California • Aurora, Colorado • Denver, Colorado + 14 more

Conditions: C3G, IC-MPGN, Renal Transplant, Complement 3 Glomerulopathy, Complement 3 Glomerulopathy (C3G), Dense Deposit Disease (DDD), Membranoproliferative Glomerulonephritis, Membranoproliferative Glomerulonephritis (MPGN), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN), C3 Glomerulopathy, C3 Glomerulonephritis, Complement 3 Glomerulonephritis
Interventions: Pegcetacoplan; Drug
Lead sponsor: Apellis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 7
States / cities: Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 3 more

Conditions: Dense Deposit Disease
Interventions: TP10; Drug
Lead sponsor: University of Iowa; Other
Eligibility: 4 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: C3G, IC-MPGN, C3 Glomerulopathy, C3 Glomerulonephritis, Complement 3 Glomerulopathy, Complement 3 Glomerulopathy (C3G), Complement 3 Glomerulonephritis, Dense Deposit Disease, DDD, Membranoproliferative Glomerulonephritis, Membranoproliferative Glomerulonephritis (MPGN), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
Interventions: Pegcetacoplan; Drug
Lead sponsor: Apellis Pharmaceuticals, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 12
States / cities: Los Angeles, California • Aurora, Colorado • Gainsville, Florida + 9 more

Search by objective public record fields.

Study on Efficacy and Safety of LNP023 in C3 Glomerulopathy Patients Transplanted and Not Transplanted

Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.

First-In-Human Clinical Study of the C3 Complement Inhibitor AMY- 101 in Healthy Male Volunteers

A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G)

Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN

Pediatric Longitudinal Glomerular Disease: a PNRC Multi-Institutional Cohort Study

Controlled Trial Evaluating Avacopan in C3 Glomerulopathy

Home Reported Outcomes in C3G Study

Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721

A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G

Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

Daratumumab in Treatment of PGNMID and C3 GN

A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471

Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies

Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN

TP10 Use in Patients With C3 Glomerulopathy (C3G)

An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis